CPRX
CATALYST PHARMACEUTICALS, INC.
Next earnings Aug 4, 2026 · consensus $0.49 EPS, $158M rev
$31.43
▲ +0.02%$31.43▲ +37.77%
over 1Y
L $19.13EODHDH $31.43
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W+0.1%
1M+0.3%
3M+32.0%
YTD+35.7%
1Y+37.7%
Buy
Conviction
Horizon
Medium (3–12mo)
12-mo target
$•••
Street · 12 analysts
Buy
Cash-rich rare-disease cash machine at 18.7x earnings with 30%+ EPS growth and a real patent overhang — buy with eyes open.
Sources: SEC EDGAR (CIK 0001369568, latest 10-Q filed 2026-05-11) · EODHD · analysis by claude-code · as of 6/25/2026, 1:14:32 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.